2025年8月21日，通化金马(000766.SZ)发布2025年中报。 公司营业总收入为6.50亿元，较去年同报告期营业总收入增加80.21万元，同比较去年同期上涨0.12%。归母净利润为1680.40万元，较去年同报告期归母净利 润增加433.57万元，实现3年连续上涨，同比较去年同期上涨34.77%。经营活动现金净流入为7804.76万元，较去年同报告期经营活动现金净流入增加3993.91 万元，同比较去年同期上涨104.80%。 公司最新资产负债率为49.91%。 公司最新毛利率为73.32%，较上季度毛利率增加1.71个百分点。最新ROE为0.74%，较去年同期ROE增加0.20个百分点。 公司较去年同报告期摊薄每股收益基本持平，实现3年连续上涨，同比较去年同期上涨34.88%。 公司最新总资产周转率为0.14次，较去年同期总资产周转率持平，同比较去年同期上涨1.19%。最新存货周转率为0.46次，较去年同期存货周转率增加0.04 次，同比较去年同期上涨9.23%。 公司股东户数为3.95万户，前十大股东持股数量为3.92亿股，占总股本比例为40.59%，前十大股东持股情况如下： | 序号 | 股东 ...

Group 1 - Tonghua Golden Horse (000766.SZ) released its semi-annual report for 2025 on August 21, 2025, showing that as of August 20, 2025, 21 institutional investors disclosed holding a total of 103 million shares, accounting for 10.68% of the total share capital [1] - The top ten institutional investors include Shanghai Mukai Trading Co., Ltd., Tonghua Yongxin Investment Co., Ltd., and several ETFs, with their combined holding ratio increasing by 2.78 percentage points compared to the previous quarter, reaching 10.59% [1] Group 2 - In the public fund sector, there was an increase in holdings from one public fund, namely the Southern CSI 1000 ETF, with an increase ratio of 0.18% [2] - Two public funds, including Innovation Medicine and Guolian An CSI Medicine 100A, reported a decrease in holdings, with a reduction ratio of 0.32% [2] - A total of 15 new public funds were disclosed this period, including several ETFs focused on the CSI 1000 and innovative medicine sectors [2] - One foreign institution, Hong Kong Central Clearing Limited, was newly disclosed this period [2]

Group 1 - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [2] - The company reported no changes in the controlling shareholder or actual controller during the reporting period [4][5] - The board of directors approved the 2025 semi-annual report and its summary, which was disclosed on the same day [14][15] Group 2 - All directors attended the board meeting that reviewed the report [1] - The board meeting was held on August 20, 2025, with all 9 directors present [11][12] - The meeting was conducted in accordance with relevant laws and regulations [13]

Core Viewpoint - Tonghua Golden Horse (000766) reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating a positive trend in financial performance despite a challenging market environment [1][2]. Financial Performance - The company achieved an operating income of 650 million yuan, a year-on-year increase of 0.12% [1]. - The net profit attributable to shareholders was 16.804 million yuan, reflecting a year-on-year growth of 34.77% [1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 14.4073 million yuan, showing a substantial increase of 125.07% year-on-year [1]. - Basic earnings per share were reported at 0.02 yuan [1]. Business Operations - Tonghua Golden Horse is engaged in the research, production, and sales of pharmaceutical products, with a business unit cluster that includes its headquarters, Shengtai Biological, Yongkang Pharmaceutical, and Yuanshou Biological [1]. - The company’s product range covers various therapeutic areas, including oncology, microbiology, cardiovascular, detoxification, digestive system, musculoskeletal system, gynecology, and neurology [1]. Research and Development - The company is focused on enhancing professional skills and quality research levels, aiming to improve its technological innovation capabilities and market influence [2]. - A self-developed national class 1.1 new drug, Succinic Dihydroaminoacridine Tablets, has received an acceptance notice from the National Medical Products Administration (NMPA) [2]. - The drug, which has complete independent intellectual property rights, is intended for the treatment of mild to moderate Alzheimer's disease and has completed phase III clinical trials from August 2017 to September 2023 [2]. Regulatory Process - The company is actively working on the new drug's registration application in compliance with NMPA regulations and guidelines [2]. - The approval process for the drug involves several uncertainties, including review timelines and market competition dynamics [2]. - The company is maintaining communication with the NMPA during the review process, which is described as a normal state for new drug evaluations [3].

证券日报网讯 8月20日晚间，通化金马发布公告称，公司第十一届董事会第十次会议审议通过了《公司 2025年半年度报告及其摘要》。 （文章来源：证券日报） ...

Core Viewpoint - Tonghua Golden Horse (000766) reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating a positive trend in financial performance despite a challenging market environment [1][2]. Financial Performance - The company achieved an operating income of 650 million yuan, a year-on-year increase of 0.12% [1]. - The net profit attributable to shareholders was 16.804 million yuan, reflecting a year-on-year growth of 34.77% [1]. - The net profit after deducting non-recurring gains and losses was 14.4073 million yuan, showing a substantial increase of 125.07% year-on-year [1]. - Basic earnings per share were reported at 0.02 yuan [1]. Business Overview - Tonghua Golden Horse is primarily engaged in the research, production, and sales of pharmaceutical products, with a diverse product range covering oncology, microbiology, cardiovascular, detoxification, digestive, musculoskeletal, gynecological, and neurological systems [1]. - The company operates through various business units, including its headquarters, Shengtai Biological, Yongkang Pharmaceutical, and Yuanshou Biological [1]. Research and Development - The company focuses on enhancing professional skills and quality research levels, aiming to improve its technological innovation capabilities and market influence [2]. - Tonghua Golden Horse is developing a self-researched national class 1.1 new drug, Succinic Dihydrogenated Aminoacridine Tablets, which has received a notice of acceptance for its market application from the National Medical Products Administration [2][3]. - The drug is intended for the treatment of mild to moderate Alzheimer's disease and has undergone various clinical trial phases since 2007 [3]. Regulatory and Market Position - The company is actively working on the registration and market launch of Succinic Dihydrogenated Aminoacridine Tablets, adhering to relevant laws and guidelines [2][3]. - The drug's approval process is currently ongoing, with the company maintaining communication with the Center for Drug Evaluation (CDE) to address any inquiries during the review process [3].

Group 1 - Weicai Technology achieved a net profit of 101 million yuan in the first half of 2025, a year-on-year increase of 831.03% [1] - The company reported an operating income of 634 million yuan, up 47.53% year-on-year, with a basic earnings per share of 0.68 yuan [1] - Weicai Technology specializes in wafer testing, chip finished product testing, and related integrated circuit testing services [1] Group 2 - Changhua Group received a project development notification from a domestic automotive company, with an expected total sales amount of approximately 190 million yuan over an 8-year lifecycle [2] - The project is set to begin mass production in the third quarter of 2026 [2] - Changhua Group focuses on the research, production, and sales of automotive metal components [2][3] Group 3 - Junhe Co. reported a net profit of 30.99 million yuan in the first half of 2025, a year-on-year decrease of 19.53% [3] - The company achieved an operating income of 578 million yuan, up 5.53% year-on-year, with a basic earnings per share of 0.08 yuan [3][4] - Junhe Co. specializes in the research, design, manufacturing, and sales of household water pumps and their accessories [4] Group 4 - Tonghua Jinma reported a net profit of 16.80 million yuan in the first half of 2025, a year-on-year increase of 34.77% [5] - The company achieved an operating income of 650 million yuan, a slight increase of 0.12% year-on-year, with a basic earnings per share of 0.0174 yuan [5] - Tonghua Jinma focuses on the research, production, and sales of pharmaceutical products [5][6] Group 5 - Xing Shuai reported a net profit of 122 million yuan in the first half of 2025, a year-on-year increase of 31.79% [8] - The company achieved an operating income of 1.132 billion yuan, up 8.59% year-on-year, with a basic earnings per share of 0.37 yuan [8] - Xing Shuai specializes in the research, production, and sales of various types of refrigeration compressor thermal protectors, starters, and temperature controllers [8] Group 6 - Ice Wheel Environment reported a net profit of 266 million yuan in the first half of 2025, a year-on-year decrease of 19.71% [9] - The company achieved an operating income of 3.118 billion yuan, down 6.92% year-on-year, with a basic earnings per share of 0.27 yuan [9] - Ice Wheel Environment focuses on the research, design, and sales of artificial environment control technology and energy comprehensive utilization technology [9][10] Group 7 - Jiangsu Huachen reported a net profit of 47.27 million yuan in the first half of 2025, a year-on-year increase of 18.37% [18] - The company achieved an operating income of 938 million yuan, up 40.46% year-on-year, with a basic earnings per share of 0.2901 yuan [18] - Jiangsu Huachen specializes in the research, production, and sales of energy-saving transformers and smart electrical equipment [18] Group 8 - Hanma Technology reported a net profit of 27.73 million yuan in the first half of 2025, reversing from a loss of 153 million yuan in the same period last year [18] - The company achieved an operating income of 2.847 billion yuan, a year-on-year increase of 50.03% [18] - Hanma Technology focuses on the production, research, and sales of heavy trucks, special vehicles, and automotive components [18] Group 9 - Tianyue Advanced announced the listing of its H-shares on the Hong Kong Stock Exchange, raising approximately 1.938 billion HKD [19] - The global offering consisted of 47.7457 million shares, with a price of 42.80 HKD per share [19] - Tianyue Advanced specializes in the research, production, and sales of silicon carbide semiconductor materials [19][20] Group 10 - Kesi Technology signed a sales framework contract worth up to 401 million yuan with Beijing Tianyuan Innovation Technology Co., Ltd. [21] - The contract is valid for two years and involves a comprehensive information integration service project [21] - Kesi Technology focuses on the research, development, manufacturing, and sales of electronic information equipment [21][22]

Group 1: Fund Companies and ETFs - 14 fund companies have submitted applications for the second batch of Sci-Tech Innovation Bond ETFs, with 8 companies applying for products listed on the Shanghai Stock Exchange and 6 on the Shenzhen Stock Exchange [1] - The second batch of ETFs will track three indices: the CSI AAA Technology Innovation Corporate Bond Index, the SSE AAA Technology Innovation Corporate Bond Index, and the SZSE AAA Technology Innovation Corporate Bond Index [1] - Multiple banks, including Industrial Bank, China Merchants Bank, and CITIC Bank, are involved in the custody of these ETFs, marking a shift from the previous batch where only Industrial Bank was the custodian [1] Group 2: Banking Sector - Several village banks in regions like Zhejiang, Guizhou, and Jilin have announced reductions in deposit interest rates, with cuts ranging from 10 to 20 basis points [1] - This trend is primarily observed among small and medium-sized banks, which are adjusting deposit rates to stabilize net interest margins amid declining trends [1] - The ongoing reduction in deposit rates is expected to continue, prompting smaller banks to rethink their reliance on high-interest deposits and develop differentiated products and services [1] Group 3: Technology and AI Market - IDC reports that the market size for large model development platforms in China is expected to reach 1.69 billion yuan in 2024, driven by applications in productivity enhancement and marketing [2] - The top six companies in this market include Baidu Smart Cloud, Alibaba Cloud, SenseTime, Zhipu AI, Telecom AI, and Xiyu Technology [2] Group 4: Automotive and Electronics - Omdia predicts that global shipments of foldable OLED screens will reach 124.6 million units by 2032, significantly higher than the estimated 23.1 million units in 2024 [2] - The growth in foldable smartphone shipments is expected to increase fivefold over the next eight years, driven by continuous innovation in new models [2] Group 5: Pharmaceutical and Animal Health - The first prescription drug for stress relief in cats, named "Miao Neng," has been launched in China, priced at 69.8 yuan for a three-pack and 124.8 yuan for a six-pack [3] - This product is noted for its rapid action, high targeting, and superior safety compared to existing alternatives in the market [3] Group 6: Corporate Developments - American Bank has reportedly hired Barclays' Sandeep Tharian to lead its Asia-Pacific credit sales business, indicating a strategic move to strengthen its presence in the region [4] - Okai Airlines and other companies have been executed for over 620 million yuan due to financial loan disputes, highlighting ongoing financial challenges within the aviation sector [4] Group 7: Market Performance - The ChiNext 50 Index surged over 3%, reaching a new high for the year, with significant trading volume across the Shanghai and Shenzhen markets [11] - Chip stocks experienced a notable rally, with companies like Cambricon reaching historical highs, while consumer stocks also showed signs of recovery [11]

格隆汇8月20日丨通化金马(000766.SZ)公布2025年半年度报告，上半年公司实现营业收入6.5亿元，同比 增长0.12%；归属于上市公司股东的净利润1680.4万元，同比增长34.77%；归属于上市公司股东的扣除 非经常性损益的净利润1440.73万元，同比增长125.07%；基本每股收益0.0174元。 ...

人民财讯8月20日电，通化金马（000766）8月20日晚间披露2025年半年报，公司上半年实现营业收入 6.5亿元，同比增长0.12%；归母净利润1680.4万元，同比增长34.77%；基本每股收益0.0174元。 ...